University Hospital Basel / Tumour Centre
University Hospital Basel coordinates cancer care in the home city of Roche and Novartis; its groups run early-phase tumour immunology trials, study breast cancer metastasis, and develop peptide radioligands such as exendin-based imaging of insulinomas.
Overview
The Tumour Centre of University Hospital Basel coordinates cancer care in a city that is also headquarters to Roche and Novartis and home to the Friedrich Miescher Institute and the University of Basel's Department of Biomedicine. Alfred Zippelius and Heinz Läubli lead tumour immunology and early-phase immunotherapy trials, Mohamed Bentires-Alj studies breast cancer metastasis, Viola Heinzelmann-Schwarz heads gynaecological oncology, and the nuclear medicine and radiopharmaceutical chemistry groups (Damian Wild, Melpomeni Fani) develop novel peptide radioligands, including exendin-based imaging of insulinomas. The hospital runs haematology and CAR-T, thoracic and visceral surgery, and radiotherapy, and hosts SAKK and pharma-sponsored trials.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to University Hospital of Basel, including child institutions. 538 works · 5,537 citations · 83% open access · 11% clinical trials · 3% reviews.
- Heinz Philipp Laubli61 works
- Alfred Zippelius59 works
- Alexander Andreas Navarini31 works
- David König28 works
- Babak Saravi28 works
- Marcus Hermann Friedrich Vetter27 works
- Lara Valeska Maul27 works
- Andreas Vollmer27 works
- Kaustubh Adhikari27 works
- Max Wilkat26 works
- Tumour immunology and early-phase immunotherapy
- Radiopharmaceutical chemistry
- Breast cancer metastasis research
- Gynaecological oncology
- Haematology and CAR-T
Similar pages
not linked directly; found by shared links- InstitutionErasmus MC Cancer Institute
Shares Novartis, PET/CT, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- CompanyMariana Oncology
- Key paperNETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Shares Novartis, PET/CT, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonSimron Singh
Shares Neuroendocrine tumours, Radioligand therapy (beta emitters).
- CompanyEvergreen Theragnostics
Shares Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonEmily K. Bergsland
Shares Neuroendocrine tumours, Radioligand therapy (beta emitters).
- CompanyPOINT Biopharma
Shares Neuroendocrine tumours, Radioligand therapy (beta emitters).
- IdeaBuild Western ytterbium-176 enrichment so lutetium-177 has more than one supplier